Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
Deutsche Version Deutsche Version
  MedUni Vienna    Intranet    MedUni Vienna - Shop    University Library    University Hospital Vienna  
 
Krebsforschung_EN.png
 
 
 
Hauptnavigation
  • Home
  • General Information
    • History
    • 50 years Institute for Cancer Research
    • Imagevideo: Institute for Cancer Research
  • Research
    • Research Focus
    • Research Laboratories
    • Scientific Services - Core Facilities
  • Teaching
    • Lectures of the Institute of Cancer Research
    • University Course Toxicology for Postgraduates
    • PhD Program Inflammation and Immunity
    • PhD Program IPPTO Translational Oncology
    • PhD Program Malignant Diseases
    • PhD Program Clinical and Experimental Oncology
  • Contact
    • Contact
    • Map
 
Research / Research Focus / Applied and Experimental Oncology / Martin Filipits
 
Subnavigation
  • Research Focus
    • Cellular and Molecular Tumorbiology
    • Applied and Experimental Oncology
      • Walter Berger
      • Martin Filipits
        • Research Projects
        • Group Members
      • Petra Heffeter
      • Michael Grusch
      • Klaus Holzmann
      • Hedwig Sutterlüty
    • Chemical Safety and Cancer Prevention
    • Tumor Progression and Metastasis
  • Research Laboratories
  • Scientific Services - Core Facilities


Inhaltsbereich

 

Martin Filipits, Assoc. Prof. Univ.-Doz. Mag. Dr.
Group Leader
E-Mail: martin.filipits [at] meduniwien [dot] ac [dot] at
Phone: +43 (0)1 40160 - 57528
Fax: +43 (0)1 40160 - 957500

Research Focus

The major aim of our research is the characterization of molecular markers which help to predict therapy response in cancer patients. These markers should allow a more rational use of existing therapies, help to identify new targets in the therapy of malignant diseases or to increase the knowledge for better therapeutic concepts and ultimately improve outcome of cancer patients. To achieve this goal, we analyze tumor tissue of cancer patients for the expression of various proteins or genetic changes.



Group Members

Videos

Selected Publications

Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only.
Filipits M, Dubsky P, Rudas M, Greil R, Balic M, Bago-Horvath Z, Singer CF, Hlauschek D, Brown K, Bernhisel R, Kronenwett R, Lancaster JM, Fitzal F, Gnant M. Clin Cancer Res. 2019 May 7. pii: clincanres.0376.2019. doi: 10.1158/1078-0432.CCR-19-0376


EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR.
Buder A, Setinek U, Hochmair MJ, Schwab S, Kirchbacher K, Keck A, Burghuber OC, Pirker R, Filipits M.
Target Oncol. 2019 Apr;14(2):197-203. doi: 10.1007/s11523-019-00623-x.

PD-1 and PD-L1 Protein Expression Predict Survival in Completely Resected Lung Adenocarcinoma.
Zaric B, Brcic L, Buder A, Brandstetter A, Buresch JO, Traint S, Kovacevic T, Stojsic V, Perin B, Pirker R, Filipits M.
Clin Lung Cancer. 2018 Nov;19(6):e957-e963. doi: 10.1016/j.cllc.2018.08.014.

Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study.
Filipits M, Dafni U, Gnant M, Polydoropoulou V, Hills M, Kiermaier A, de Azambuja E, Larsimont D, Rojo F, Viale G, Toi M, Harbeck N, Prichard KI, Gelber RD, Dinh P, Zardavas D, Leyland-Jones B, Piccart-Gebhart MJ, Dowsett M; TransHERA investigators.
Clin Cancer Res. 2018 Jul 1;24(13):3079-3086. doi: 10.1158/1078-0432.CCR-17-3473

Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC.
Buder A, Hochmair MJ, Schwab S, Bundalo T, Schenk P, Errhalt P, Mikes RE, Absenger G, Patocka K, Baumgartner B, Setinek U, Burghuber OC, Prosch H, Pirker R, Filipits M.
J Thorac Oncol. 2018 Jun;13(6):821-830. doi: 10.1016/j.jtho.2018.02.014.

 

All Publications:

PubMedDataBase

 
Print
 
 
© MedUni Wien | Publishing information | Terms of use | Data Protection | Accessibility | Contact